Giant Cell Arteritis Market Shift Driven by Personalized Medicine Adoption

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Giant-Cell Arteritis Market Progress Between 2026 And 2030?

The giant-cell arteritis market has experienced consistent growth in recent years. It is projected to increase from $1.12 billion in 2025 to $1.18 billion in 2026, at a compound annual growth rate (CAGR) of 4.9%. The historical expansion of this market can be attributed to an aging population, the continued reliance on corticosteroid therapy, improvements in rheumatology care, the broader availability of hospital-based treatment, and increased awareness of the disease.

The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $1.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth during the projected period include the approval of biologic drugs, advancements in immunology research, enhanced diagnostic procedures, tailored treatments for vasculitis, and the proliferation of specialized clinics. Key trends anticipated during the same period encompass a greater uptake of biologic therapies, a heightened emphasis on prompt and precise diagnosis, wider application of corticosteroid-reducing treatments, better long-term monitoring of the disease, and increased understanding regarding the prevention of vision loss.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Which Drivers Are Supporting The Giant-Cell Arteritis Market Growth?

The market for giant-cell arteritis is projected to expand due to an increasing focus on personalized medicine. This approach customizes medical care based on unique patient attributes, including genetic makeup, daily habits, and surroundings. Its rise is driven by progress in genomics, biotechnology, and data analytics, which facilitates targeted treatments that enhance effectiveness and minimize side effects for patients. For giant-cell arteritis (GCA), personalized medicine offers the benefit of customized therapies, considering individual patient elements like genetic predispositions, immune system profiles, and how the disease presents itself. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit entity, stated that personalized medicines constituted over one-third of the new drug approvals by the U.S. Food and Drug Administration (FDA) in 2023, marking the fourth consecutive year this trend occurred. In 2023, the FDA sanctioned 16 novel personalized therapies specifically designed for rare diseases, representing a substantial rise from six approvals recorded in 2022. Furthermore, the 2023 approvals included seven cancer medications and three treatments targeting a range of other diseases and health conditions. Consequently, the increasing emphasis on personalized medicine is a key driver for the expansion of the giant-cell arteritis market.

What Segment Categories Shape The Giant-Cell Arteritis Market Segment Landscape?

The giant-cell arteritis market covered in this report is segmented –

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Which Trends Are Expected To Impact The Giant-Cell Arteritis Market?

Leading companies engaged in the giant-cell arteritis market are creating new products, such as biosimilars, to expand available treatments and fulfill the unmet medical requirements of patients. A biosimilar is a biological drug that exhibits high similarity to an already sanctioned biological product, lacking any clinically meaningful distinctions in terms of its safety, purity, and potency. For example, in April 2024, Fresenius SE & Co. KGaA, a healthcare company based in Germany, launched Tocilizumab-aazg in the US for managing chronic autoimmune diseases. This biosimilar is approved for conditions including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval relied on findings from a randomized, double-blind, single-dose, parallel phase 1 trial comparing its pharmacokinetics, safety, and immunogenicity with both US and EU reference tocilizumab across three patient groups.

Who Are The Companies Operating Across The Giant-Cell Arteritis Market Value Chain?

Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol‑Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

Get The Full Giant-Cell Arteritis Market Report:

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Where Is The Giant-Cell Arteritis Market Primarily Concentrated By Region?

North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Giant-Cell Arteritis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2026, By The Business Research Company

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Small Cell Backhaul Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-cell-backhaul-global-market-report

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795